Nurix Therapeutics

CompanyUnited States

Nurix Therapeutics develops one asset, in phase 1 (bexobrutideg in chronic lymphocytic leukemia). Mostly small molecule acting on proteostasis and BTK; based in the United States.

1
Asset
Furthest: Phase 1; 3
Trials: 0
Signals

Pipeline

1

bexobrutideg
Targeted protein degrader (PROTAC) targeting Bruton tyrosine kinase (BTK).
Phase 1, Small molecule, Proteostasis, BTK, chronic lymphocytic leukemia

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials3
Similar companies6

Updated 10 Oct 2026 · 5 sources